Navigation Links
Dr. David Heimbrook Appointed Chief Executive Officer of SAIC-Frederick, Inc.
Date:5/24/2011

MCLEAN, Va., May 24, 2011 /PRNewswire/ -- Science Applications International Corporation (SAIC) (NYSE: SAI) announced today the appointment of Dr. David Heimbrook as chief executive officer of SAIC-Frederick, Inc., a wholly owned subsidiary of SAIC, effective May 31. Heimbrook will succeed Dr. Larry Arthur, who has served as CEO since 2000 and will remain with SAIC-Frederick as chief scientist.

SAIC-Frederick provides operations and technical support to the National Cancer Institute's (NCI's) Federally Funded Research and Development Center (FFRDC) in Frederick, Md. The FFRDC is one of only 38 national laboratories in the United States and the only one solely dedicated to cancer and HIV/AIDS research.  The FFRDC strives to develop new technologies and translate scientific discoveries into novel agents for the prevention, diagnosis, and treatment of cancer and AIDS.  SAIC has supported NCI-Frederick since 1995 and in 2008 was awarded a new 10-year contract by the U.S. Department of Health and Human Services to continue that work.  

Heimbrook will be responsible for the comprehensive management and oversight of all scientific and business activities conducted on the contract.  He will lead SAIC-Frederick's staff of approximately 2,000 scientific, technical, and support professionals who perform basic and applied research in cancer and AIDS, and maintain a full suite of advanced technologies in areas such as nanotechnology, genomics and biomedical imaging.

Heimbrook brings more than 20 years of experience and progressive responsibility in cancer research, translational research and organizational management.  Prior to joining SAIC-Frederick, he was the global head of discovery for the Oncology Discovery and Translation Area of Hoffman-LaRoche, Inc.  Leading three cancer research sites, Heimbrook was responsible for developing and implementing Roche's oncology research strategy, including personalized healthcare and partnering relationships, and transitioning compounds through clinical proof-of-concept to pivotal registration studies.  Heimbrook previously held positions with Merck Research Laboratories and Smith Kline & French Laboratories.

Heimbrook earned his Ph.D. in molecular biophysics and biochemistry from Yale University, a master's degree in molecular biophysics and biochemistry from Yale University, and a bachelor's degree in chemistry from Duke University.  He will report to Joe Craver, president of SAIC's Health, Energy and Civil Solutions Group.

"We are deeply appreciative of Larry Arthur's outstanding leadership over the past 11 years," said Craver.  "Looking forward, we are confident Dave's extensive knowledge and experience in the national healthcare and scientific research community will be of tremendous benefit to the important work SAIC is providing for NCI's world-class research facility.  He has an outstanding track record of managing research organizations, and I anticipate he will deliver exceptional service and leadership to NCI and to our employees."

About SAICSAIC is a FORTUNE 500® scientific, engineering, and technology applications company that uses its deep domain knowledge to solve problems of vital importance to the nation and the world, in national security, energy and the environment, critical infrastructure, and health.  The company's approximately 43,000 employees serve customers in the U.S. Department of Defense, the intelligence community, the U.S. Department of Homeland Security, other U.S. Government civil agencies and selected commercial markets.  Headquartered in McLean, Va., SAIC had annual revenues of $11.1 billion for its fiscal year ended January 31, 2011.  For more information, visit www.saic.com.  SAIC:  From Science to Solutions®

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in SAIC's Annual Report on Form 10-K for the period ended January 31, 2011, and other such filings that SAIC makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.Contact:

Melissa Koskovich

Laura Luke (703) 676-6762

(703) 676-6533Melissa.l.koskovich@saic.com

laura.luke@saic.com
'/>"/>

SOURCE SAIC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
3. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
4. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
5. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
6. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
8. David H. Murdock Research Institute Taps Waters for Laboratory Technology
9. PercSys Names David Auth and Howard Palefsky to Its Board of Directors
10. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
11. BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016  The Multiple Myeloma ... from the MMRF CoMMpass Study SM —the largest and ... precision medicine in multiple myeloma—will be presented at the ... Meeting & Exposition in San Diego ... to optimize treatment strategies, as well as identify pathways ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... share findings demonstrating the value of DNA microarray comparative genomic hybridization (array ... San Antonio Breast Cancer Symposium. Using molecular test results from tumors with ...
(Date:12/2/2016)... ... 2016 , ... Orthogonal, a Chicago-based medical device software company, ... 510(k) clearance for their flagship medical device, SimplECG. , With this FDA approval, ... rely on cloth-based nanosensors. While other companies have attempted to focus on wearable ...
(Date:12/2/2016)... Laboratories, a world leader in rapid infectious disease tests, introduced the Company,s newest product, ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited by ... the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
Breaking Biology News(10 mins):